The Case for Physician-Led Site Operations in Device and Drug Trials

A recurring failure mode in multi-site trials is the gap between protocol design and day-to-day operational execution — a gap that widens when the clinical judgment required to interpret ambiguous protocol language sits several layers removed from the people running study visits.

Mount Clinical Research's founding team is composed entirely of credentialed clinicians: nine professionals spanning anesthesiology and pain medicine, neurosurgery, psychiatry, nursing science, pharmacy, and bioanalytical science. Every therapeutic area we support is overseen by a board-certified or board-eligible specialist serving directly as Principal Investigator, Sub-Investigator, or clinical consultant.

In practice, this means protocol ambiguities get resolved by someone with the clinical training to make that judgment call correctly the first time, rather than escalated through a chain of non-clinical site staff. It also means safety signals are reviewed by physicians embedded in daily operations, not just during scheduled monitoring visits.

For device trials in particular — spinal cord stimulation, peripheral nerve stimulation, deep brain stimulation — this matters acutely. Device programming, patient selection, and adverse event assessment all benefit from direct physician involvement that a purely administrative site structure cannot replicate.

We believe this is one of the more durable advantages a small, physician-led site can offer sponsors relative to larger, more administratively layered CRO networks.